Strong Revenue Growth
Q3 2024 revenue of $143 million was at the high end of guided range, representing a 32% year-over-year growth, driven by the Cornell acquisition and 4% organic growth.
Improved EBITDA Margins
Adjusted EBITDA margins were 24.6% with expectations for additional margin expansion as market conditions improve and synergy benefits from the Cornell acquisition are realized.
Medtech & Specialty Audio Segment Performance
Segment revenue grew 4% sequentially and 10% year-over-year, driven by new product adoption and technology advancements.
Precision Devices Segment Growth
Revenues grew 57% year-over-year due to the Cornell acquisition, with significant margin improvements due to cost synergies and operational enhancements.
Successful Cost Management and Cash Flow
Q3 cash from operations was $53 million, exceeding expectations. Company reduced bank borrowings by $38 million, increasing overall financial flexibility.